Non-coding Sequences Having No Known Regulatory Function Which Are Adaptors Or Linkers For Vector Or Gene Contruction Patents (Class 536/24.2)
  • Patent number: 6225457
    Abstract: The invention provides murF2 polypeptides and polynucleotides encoding murF2 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing murF2 polypeptides to screen for antibacterial compounds.
    Type: Grant
    Filed: May 4, 1999
    Date of Patent: May 1, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Sanjoy Biswas, James Raymond Brown, Martin K R Burnham, Alison Francis Chalker, David John Holmes, Karen Anne Ingraham, Thomas B Mathie, Richard Lloyd Warren, Magdalena Zalacain
  • Patent number: 6218186
    Abstract: A hybrid viral vector for transfer of selected genes to cells and mammals is provided. The vector is a hybrid of human immunodeficiency-based lentivirus and murine stem cell retrovirus.
    Type: Grant
    Filed: November 12, 1999
    Date of Patent: April 17, 2001
    Assignee: Trustees of the University of Pennsylvania
    Inventors: John Kim Choi, Alan M. Gewirtz
  • Patent number: 6218123
    Abstract: A new technology is described that allows for the rapid and efficient construction of complex cDNA libraries from cultured eukaryotic cells. The technology exploits eukaryotic biology by using transgenic constructs that have been nonspecifically inserted into the genome to facilitate the expression of nuclear genes as fusion transcripts. The invention further allows one to specifically subclone the corresponding fusion transcripts into highly complex cDNA libraries. The libraries are easily characterized by molecular analysis techniques such as hybridization, and individual clones can be directly sequenced to generate a sequence database of the cellular portion of the fusion transcripts.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: April 17, 2001
    Assignee: Lexicon Genetics Incorporated
    Inventors: Michael Nehls, Brian Zambrowicz, Glenn Friedrich, H. Earl Ruley, Arthur T. Sands, Sigrid Wattler
  • Patent number: 6214547
    Abstract: The present invention relates to synthetic leader peptide sequences for secreting polypeptides in yeast.
    Type: Grant
    Filed: January 23, 1998
    Date of Patent: April 10, 2001
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Børglum Kjeldsen, Svend Havelund, Annette Frost Petterson, Per Balschmidt
  • Patent number: 6211352
    Abstract: The present invention relates to the identification, cloning and sequencing of nucleic acid molecules encoding an isoform of the enzyme glutamic acid decarboxylase and further relates to the use of these molecules and/or peptides and polypeptides encoded thereby in diagnostic tests for Insulin Dependent Diabetes Mellitus and other diseases in which glutamic acid decarboxylase is an autoantigen and in the treatment of patients suffering from these diseases.
    Type: Grant
    Filed: July 29, 1998
    Date of Patent: April 3, 2001
    Assignee: Amrad Corporation Limited
    Inventors: Leonard Harrison, Margot Honeyman, David Cram, Henry De Aizpurua
  • Patent number: 6211351
    Abstract: The invention is based on the discovery that recombinagenic oligonucleobases are active in prokaryotic cells that contain a strand transfer activity (RecA) and mismatch repair activity (MutS). Using this system a type of Duplex Mutational Vector termed a Heteroduplex Mutational Vector, was shown to be more active in prokaryotic cells than the types of mutational vectors heretofore tested. Further improvements in activity were obtained by replacing the tetrathymidine linker by a nuclease resistant oligonucleotide, such as tetra-2′-O-methyl-uridine, to link the two strands of the recombinagenic oligonucleobase and removing the DNA-containing intervening segment. The claims concern Duplex Mutational Vectors that contain the above improvements. In an alternative embodiment the claims concern the use of Duplex Mutational Vectors in prokaryotic cells.
    Type: Grant
    Filed: October 28, 1999
    Date of Patent: April 3, 2001
    Assignee: ValiGen (US), Inc.
    Inventors: Ramesh Kumar, Richard A. Metz
  • Patent number: 6211349
    Abstract: The novel discovery that protonated nucleic acids inhibit bacterial growth is reported and methods for the preparation and therapeutic use of nuclease resistant and acid resistant protonated/acidified nucleic acids for administration to animals including man, to treat or prevent a bacterial infection are described.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: April 3, 2001
    Assignee: Oligos Etc., Inc.
    Inventors: Roderic M. K. Dale, Amy Arrow, Steven L. Gatton, Terry Thompson
  • Patent number: 6183995
    Abstract: This invention provides methods for the isolation of complete representation of cellular messenger ribonucleic acid from wax-embedded tissue samples. Expression of genes of interest can thus be fortuitously determined and cDNA probes can be readily developed.
    Type: Grant
    Filed: September 5, 1997
    Date of Patent: February 6, 2001
    Assignee: LifeSpan BioSciences, Inc.
    Inventors: Glenna C. Burmer, Amanda A. Ford, Joseph P. Brown
  • Patent number: 6175002
    Abstract: An improvement in adaptor-based sequence analysis is provided that addresses the problems created by self-ligation of target polynucleotides that have complementary ends. The improvement includes preparation of target polynucleotides with dephosphorylated 5′ strands and the use of adaptors having a 3′ blocking group. In a preferred embodiment, adaptors are ligated to target polynucleotides by a single strand, 3′ blocking groups are removed, the adjacent 5′ hydroxyl of the target polynucleotide is phosphorylated, and the ligation of the adaptor is completed by treatment with a ligase.
    Type: Grant
    Filed: January 5, 1999
    Date of Patent: January 16, 2001
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Robert B. DuBridge, Glenn Albrecht, Sydney Brenner, Sergei M. Gryaznov, Sarah N. McCurdy
  • Patent number: 6172218
    Abstract: The invention provides a method of tracking, identifying, and/or sorting classes or subpopulations of molecules by the use of oligonucleotide tags. Oligonucleotide tags of the invention comprise oligonucleotides selected from a minimally cross-hybridizing set. Preferably, such oligonucleotides each consist of a plurality of subunits 3 to 9 nucleotides in length. A subunit of a minimally cross-hybridizing set forms a duplex or triplex having two or more mismatches with the complement of any other subunit of the same set. The number of oligonucleotide tags available in a particular embodiment depends on the number of subunits per tag and on the length of the subunit. An important aspect of the invention is the use of the oligonucleotide tags for sorting polynucleotides by specifically hybridizing tags attached to the polynucleotides to their complements on solid phase supports.
    Type: Grant
    Filed: June 5, 1998
    Date of Patent: January 9, 2001
    Assignee: Lynx Therapeutics, Inc.
    Inventor: Sydney Br{umlaut over (e)}nner
  • Patent number: 6172214
    Abstract: The invention provides a method of tracking, identifying, and/or sorting classes or subpopulations of molecules by the use of oligonucleotide tags. Oligonucleotide tags of the invention comprise oligonucleotides selected from a minimally cross-hybridizing set. Preferably, such oligonucleotides each consist of a plurality of subunits 3 to 9 nucleotides in length. A subunit of a minimally cross-hybridizing set forms a duplex or triplex having two or more mismatches with the complement of any other subunit of the same set. The number of oligonucleotide tags available in a particular embodiment depends on the number of subunits per tag and on the length of the subunit. An important aspect of the invention is the use of the oligonucleotide tags for sorting polynucleotides by specifically hybridizing tags attached to the polynucleotides to their complements on solid phase supports.
    Type: Grant
    Filed: August 7, 1998
    Date of Patent: January 9, 2001
    Assignee: Lynx Therapeutics, Inc.
    Inventor: Sydney Brenner